hsa-miR-17-3p在膀胱癌中的表达及其与预后、免疫浸润及免疫治疗效果的关系  

Expression of hsa-miR-17-3p in bladder cancer and its relationship with prognosis,immune infiltration,and immunotherapy efficacy

作　　者：蒋曼妃 王宝锋 黄清迈 胡强华 车宪平 JIANG Man-fei;WANG Bao-feng;HUANG Qing-mai;HU Qiang-hua;CHE Xian-ping(Department of Urology,the Second Affiliated Hospital of Hainan Medical University,Haikou 570311,Hainan,CHINA)

机构地区：[1]海南医科大学第二附属医院泌尿外科,海南海口570311

出　　处：《海南医学》2025年第7期913-918,共6页Hainan Medical Journal

基　　金：海南省自然科学基金(编号:819MS127);海南省科技厅高层次人才项目(编号:822RC842)。

摘　　要：目的探讨hsa-miR-17-3p在膀胱癌(BLCA)中的表达及其与预后、免疫浸润及免疫治疗效果的关系。方法从TCGA数据库(截至2024年)下载418例BLCA组织样本和19例正常组织样本的miRNA表达数据以及相应的临床数据。首先,使用R语言中的“limma”包分析hsa-miR-17-3p在BLCA中的表达情况,随后,使用R语言中的“pROC”包绘制受试者工作特征(ROC)曲线分析hsa-miR-17-3p对BLCA的诊断价值,并使用R语言中的“survival”和“survminer”包绘制生存曲线,并通过“rms”“regplot”“survcomp”和“survival”包构建列线图和校准曲线分析hsa-miR-17-3p在BLCA中的预后价值。此外,从肿瘤免疫功能缺陷与排斥(TIDE)数据库下载免疫治疗打分数据,分析hsa-miR-17-3p与免疫细胞浸润的相关性及其对免疫治疗的影响。最后,通过TargetscanHuman、miRDB和mirwalk数据库预测hsa-miR-17-3p的靶基因,并利用Venny工具对三者预测的靶基因取交集,并通过DAVID对交集靶基因进行GO和KEGG富集分析。结果BLCA肿瘤组织中hsa-miR-17-3p的表达量为(8.962±0.042)TPM,明显高于正常组织的(7.043±0.038)TPM,差异有显著统计学意义(P<0.001)。K-M生存曲线显示,hsa-miR-17-3p高表达组的总生存期优于低表达组,差异有显著统计学意义(P<0.001)。ROC曲线下面积为0.920,表明hsa-miR-17-3p在诊断BLCA中具有较高的特异性和敏感性。1、3、5年的总生存率分别为0.91、0.716和0.61,校准曲线的C-index为0.665,说明hsa-miR-17-3p预测BLCA的生存期结果的准确性较高。hsa-miR-17-3p免疫细胞浸润的相关性分析发现,其与NK细胞和CD8+T细胞呈正相关(P<0.05),而与调节性T细胞和单核细胞呈负相关(P<0.05),且高表达组的TIDE评分明显低于低表达组,差异有统计学意义(P<0.05)。三个数据库预测的靶基因交集获得25个交集靶基因。25个交集靶基因进行GO分析显示,其功能主要与细胞内信号转导途径、蛋白质的质膜定位以及质膜到内Objective To investigate the expression of hsa-miR-17-3p in bladder cancer(BLCA)and its relationship with prognosis,immune infiltration,and immunotherapy efficacy.Methods miRNA expression data and corresponding clinical data from 418 BLCA tissue samples and 19 normal tissue samples were downloaded from The Cancer Genome Atlas(TCGA)database(up to 2024).The"limma"package in R was used to analyze hsa-miR-17-3p expression in BLCA.The"pROC"package was used to plot receiver operating characteristic(ROC)curves to evaluate the diagnostic value of hsa-miR-17-3p.The"survival"and"survminer"packages were used to generate survival curves,and the"rms,""regplot,""survcomp,"and"survival"packages were used to construct nomograms and calibration curves to assess the prognostic value of hsa-miR-17-3p.Immune therapy scoring data were downloaded from the Tumor Immune Dysfunction and Exclusion(TIDE)database to analyze the correlation between hsa-miR-17-3p and immune cell infiltration,as well as its impact on immunotherapy.Finally,TargetscanHuman,miRDB,and mirwalk databases were used to predict target genes of hsa-miR-17-3p,and the Venny tool was used to identify overlapping target genes.Functional enrichment analysis of overlapping target genes was performed using DAVID for Gene Ontology(GO)and Kyoto Encyclopedia of Genes and Genomes(KEGG)pathways.Results The expression of hsa-miR-17-3p in BLCA tissues was(8.962±0.042)TPM,significantly higher than(7.043±0.038)TPM in normal tissues(P<0.001).Kaplan-Meier survival curves showed that the high-expression group had better overall survival than the low-expression group(P<0.001).The area under the ROC curve was 0.920,indicating high specificity and sensitivity of hsa-miR-17-3p in diagnosing BLCA.The 1-,3-,and 5-year overall survival rates were 0.91,0.716,and 0.61,respectively,with a calibration curve C-index of 0.665,demonstrating high accuracy in predicting BLCA survival.Correlation analysis revealed that hsa-miR-17-3p was positively correlated with NK cells and CD8+T cells(P<0.05),but neg

关 键 词：hsa-miR-17-3p 膀胱癌 癌症基因组图谱 免疫细胞浸润 富集分析 

分 类 号：R737.14[医药卫生—肿瘤]